Document is current
Any future updates will be listed below
-
Authors
Ye, Wei https://orcid.org/0000-0002-3980-8547
Dang, Yamei
Wang, Yuan https://orcid.org/0009-0008-5688-9589
Yang, Qiqi
Zhang, Hui https://orcid.org/0000-0003-0698-4744
Ye, Chuantao https://orcid.org/0000-0002-6963-2757
Wei, Jing https://orcid.org/0009-0008-4309-6395
Pei, Jiawei
Pei, Xuemin
Jiang, Dongshen
Yang, Xiaojing
Jin, Xiaolei
Ma, Hongwei
Liu, He
Zhang, Liang
Cheng, Linfeng
Dong, Yangchao
Lei, Yingfeng https://orcid.org/0000-0002-1482-6124
Xu, Zhikai https://orcid.org/0000-0002-8893-8444
Zhang, Fanglin https://orcid.org/0000-0003-2039-509X
-
Funding
Funding for this research was provided by:
Fourth Military Medical University (2022ZZXM044,)
Fourth Military Medical University (2025KXKT115)
National Natural Science Foundation of China
National Key Research and Development Program of China Key Research and Development Project of Shaanxi Province
- License Information
-
More Information
Article History
Received: 9 April 2024
Accepted: 24 February 2026
First Online: 14 March 2026
Competing interests
: Authors W.Y., F.L.Z., Y.D., L.F.C., H.Z., L.Z., H.L., and Z.K.X. are inventors on a provisional patent application filed in China (Application No. CN202310156260.7) related to the prefusion-stabilized HTNV glycoprotein vaccine design described in this study. All other authors declare no competing interests.
